Medicinefromwww.scientificamerican.com1 week agoWhy the FDA rejected a breakthrough' melanoma drugRP1, an oncolytic immunotherapy, shows promise for melanoma patients unresponsive to traditional treatments, but FDA approval remains uncertain.